⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies

Michael Wichroski Si-Qi Liu Lauren M. Zasadil Joseph L. Benci Patrick C. Gedeon Kendall J. Condon Suhasini Joshi Shana Posy Patrick Carlson Alison Maier Jiao Shen Rakeeb Kureshi Yuka Amako Tai Wang Ryan L. Powles Yanyun Li Tho Lai Igor Katsyv Hongchen Qiu Huilin Qi Jessica Wong Dandan Zhao Dana Banas Joelle M. Onorato Gregory Locke Xueer Chen Wen‐Chi Chou Erica Cook Abigail E. Witt Christopher M. Barbieri Hong Zhang Jonathan B. Olsen Alba Font‐Tello Eugene Drokhlyansky Denise C. Grünenfelder Louis Chupak Tyler A. Longmire Jon C. Jones Travis J. Hollmann David Kugler John N. Feder Raphael Bueno John C. Wain Pallavur Sivakumar Yu Liu Stephanie K. Dougan Cloud P. Paweletz David A. Barbie Emma Lees

View Full Paper

Ask AI

Bookmark

Share

Key Points

The dual inhibitor BMS-986408 enhances PD-1 checkpoint and CAR T-cell immunotherapies.
Characterization of DGKα and DGKζ inhibition reveals a potential breakthrough in immunotherapy.
This analysis highlights the importance of targeting dual pathways for optimal immune response.
Future studies may explore expanded applications of this dual inhibition in cancer treatment.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Personalized immunotherapies improve outcomes in T-cell responses by inhibiting DGKα and DGKζ, suggesting enhanced efficacy.

Abstract

Fig. S4. Mono-selective DGKα and DGKζ inhibitor characterization.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wichroski et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5a8 https://doi.org/10.1158/2326-6066.30029422

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
2Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
3Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
4Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
5Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
6Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies2025
7Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408Original Research · 2025 · 2 citations
8Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual InhibitorOriginal Research · 2026